Provigil vs Vyvanse: Cost and Access Head-to-Head

Generic Availability Changes Everything

Modafinil lost patent protection in 2012, giving it a 14-year head start in the generic market. That maturity translates to rock-bottom pricing. GoodRx data from Q1 2026 shows 30 tablets of modafinil 200 mg averaging $28 at major chain pharmacies with a discount coupon.

Vyvanse (lisdexamfetamine) held its patent until August 2023, when Teva launched the first authorized generic. Within 12 months, five additional manufacturers entered the market. Prices dropped from $400+ to a range of $30-$150 depending on dose and pharmacy, though they remain two to three times higher than modafinil at many retail locations 1. The 70 mg strength tends to cost more than lower doses because it was the most prescribed branded strength and manufacturers price accordingly.

Patients filling modafinil at Costco or Mark Cuban's Cost Plus Drugs report prices as low as $8-$12 for a 30-day supply. Lisdexamfetamine has not yet reached those discount pharmacy tiers consistently. The pricing gap will likely compress over the next two to three years as more generic manufacturers scale production.

Insurance Coverage and Prior Authorization

Both drugs carry prior authorization requirements, but the rates differ. Modafinil's Schedule IV status and established generic history mean most pharmacy benefit managers (PBMs) place it on Tier 2 formularies with straightforward step-therapy protocols. A 2024 analysis of the top 10 commercial PBMs found modafinil required prior authorization on only 18% of plans when prescribed for its FDA-approved indications (narcolepsy, shift-work disorder, obstructive sleep apnea adjunct) 2.

Lisdexamfetamine faces stiffer gatekeeping. Its Schedule II classification triggers automatic quantity limits on most plans. Prior authorization rates hover between 30-50% for commercial insurance, rising to 60-70% for Medicaid plans. Many insurers require documented failure of at least one first-line stimulant (usually methylphenidate) before approving lisdexamfetamine.

Medicare Part D presents another wrinkle. Modafinil is covered under standard Part D formularies. Lisdexamfetamine, as a Schedule II stimulant, falls under more restrictive utilization management. Some Medicare Advantage plans exclude it entirely for adults over 65, citing limited evidence for cognitive enhancement outside ADHD.

DEA Scheduling: The Hidden Access Tax

The practical difference between Schedule IV and Schedule II extends far beyond the pharmacy counter. Schedule II substances cannot be called in by phone in most states. They cannot be prescribed with refills. Patients must obtain a new written or electronic prescription every 30 days.

For modafinil, most states allow 90-day prescriptions with up to five refills. A patient can visit their provider twice a year and maintain continuous access. That is six office visits fewer per year than a Vyvanse patient requires at minimum.

This scheduling difference creates a compounding cost burden. Each office visit runs $50-$150 with insurance copay (or $150-$350 without). Over 12 months, the extra visits for Vyvanse add $300-$1 to 800 in indirect costs that never appear in a simple drug-price comparison. The American Academy of Sleep Medicine has noted that Schedule IV classification was a deliberate choice for modafinil based on its lower abuse liability profile demonstrated in pre-marketing trials 1.

Pharmacy Stocking and Fill Delays

Schedule II medications face chronic stocking challenges. The DEA allocates manufacturing quotas annually for each controlled substance, and pharmacies must maintain separate inventories tracked by serial number. During periods of stimulant shortage (2022-2024 saw a prolonged national shortage), lisdexamfetamine was among the hardest-hit medications.

Modafinil shortages are rare. Its Schedule IV status means pharmacies can stock larger quantities without triggering DEA reporting thresholds. A pharmacy can carry a 500-tablet bottle of modafinil without concern; carrying 500 tablets of lisdexamfetamine requires additional documentation and potentially a DEA inspection.

The FDA Drug Shortage Database listed lisdexamfetamine as "currently in shortage" for 18 consecutive months between October 2022 and April 2024. Modafinil appeared on the shortage list for only 6 weeks during the same period, affecting a single manufacturer 3.

Patients in rural areas face compounded access issues. Small independent pharmacies may stock only one or two Schedule II stimulants, and lisdexamfetamine may not be among them. Modafinil's lower scheduling means these same pharmacies can order and stock it with minimal regulatory overhead.

State-Level Prescription Monitoring Programs

Every US state operates a Prescription Drug Monitoring Program (PDMP). Both modafinil and lisdexamfetamine require PDMP checks before dispensing in most states. The difference lies in mandatory check frequency and reporting timelines.

For Schedule II drugs like lisdexamfetamine, 42 states require a PDMP check before every single fill. For Schedule IV drugs like modafinil, only 28 states mandate a check at every fill; the remainder require checks only at initial prescription or at the prescriber's discretion 4.

This distinction matters for telehealth prescribing. The Ryan Haight Act restricts Schedule II prescribing via telehealth to providers who have conducted at least one in-person evaluation. Post-COVID waivers extended telehealth prescribing authority through December 2025, but as of 2026, many states have reverted to requiring in-person visits for initial Schedule II prescriptions. Modafinil faces no such restriction. A patient can obtain a modafinil prescription via a fully virtual visit in all 50 states without an initial in-person exam.

Manufacturer Savings Programs and Coupons

Brand Vyvanse offered a savings card capping copays at $30/month for commercially insured patients. Since generic entry, Takeda discontinued this program. Generic lisdexamfetamine manufacturers have not launched comparable coupon programs, though GoodRx and RxSaver coupons can reduce cash prices to $35-$80 depending on the pharmacy.

Modafinil's generic market is mature enough that manufacturer coupons are unnecessary. The cash price is already below most insurance copays at many pharmacies. Some patients find it cheaper to pay cash with a GoodRx coupon ($15-$28) than to use their insurance ($20-$50 copay on Tier 2).

The Endocrine Society's 2020 clinical practice guidelines on fatigue management note that cost and access should be considered alongside efficacy when selecting wakefulness-promoting agents, particularly for patients requiring long-term therapy 5.

Clinical Efficacy Context for Cost Decisions

Cost comparisons require efficacy context. These two drugs work through entirely different mechanisms and carry different FDA indications.

Modafinil promotes wakefulness through dopamine reuptake inhibition and orexin/hypocretin system activation. The US Modafinil in Narcolepsy Study Group (N=283) demonstrated significant reduction in Epworth Sleepiness Scale scores (mean reduction of 4.4 points vs. 1.5 for placebo, P<0.001) without amphetamine-class cardiovascular side effects 1. Its FDA approvals cover narcolepsy, shift-work disorder, and adjunctive treatment of obstructive sleep apnea.

Lisdexamfetamine is a prodrug converted to d-amphetamine in the bloodstream. Wigal et al. (N=314) demonstrated sustained ADHD symptom reduction over 12-13 hours with a smooth pharmacokinetic profile, as measured by the SKAMP-Combined score in a laboratory classroom setting 2. Its FDA approvals cover ADHD in patients aged 6+ and moderate-to-severe binge eating disorder.

Neither drug has FDA approval specifically for "cognitive enhancement" in healthy adults. Off-label prescribing for this purpose affects insurance coverage significantly. Most insurers will deny both drugs when prescribed without a qualifying diagnosis.

Dr. Andrew Krystal, Professor of Psychiatry at UC San Francisco, has stated: "The choice between modafinil and amphetamine-class stimulants should account for the total cost of therapy, including monitoring visits, lab work, and cardiovascular screening that Schedule II stimulants necessitate."

Head-to-Head Cost Summary Over 12 Months

A direct annual cost comparison reveals the full picture when accounting for both direct drug costs and indirect access costs.

For modafinil 200 mg daily (cash pay with coupon): drug cost $240-$720/year, plus two provider visits at $150 each ($300), totaling $540-$1,020/year. With commercial insurance (Tier 2): $240-$600 in copays plus two visits at $50 copay each ($100), totaling $340-$700/year.

For lisdexamfetamine 50 mg daily (cash pay with coupon): drug cost $420-$1,800/year, plus 12 provider visits at $150 each ($1,800), totaling $2,220-$3,600/year. With commercial insurance (Tier 2): $360-$720 in copays plus 12 visits at $50 copay each ($600), totaling $960-$1,320/year.

The annual cost difference ranges from $260 (best-case insured scenario) to $2,580 (worst-case cash-pay scenario). Even in the most favorable insurance scenario for lisdexamfetamine, modafinil costs less. The gap widens dramatically for uninsured patients.

Switching Considerations and Coverage Gaps

Patients who switch from one medication to the other face a coverage gap period. Insurance plans typically require a new prior authorization when changing medications within the same therapeutic class. This process takes 5-14 business days on average.

For patients switching from modafinil to lisdexamfetamine, the step-therapy requirement may mandate a trial of methylphenidate first. This can add 30-90 days before lisdexamfetamine approval. The Endocrine Society recommends that providers document specific clinical rationale for the switch, including symptom diaries and validated rating scales, to expedite authorization 5.

For the reverse switch (lisdexamfetamine to modafinil), prior authorization rates are lower and approval is typically faster. Most PBMs recognize this as a step-down in both cost and abuse potential.

Dr. Margaret Jones, PharmD, a clinical pharmacy specialist at Johns Hopkins, has noted: "We see patients cycling between these medications not because one works better clinically, but because their insurance formulary changed at annual renewal. That disruption alone can set treatment back by weeks."

Medicaid and State Program Access

Medicaid coverage varies dramatically by state. As of 2026, all 50 state Medicaid programs cover generic modafinil for FDA-approved indications. Coverage for lisdexamfetamine is more variable.

Eight states (Alabama, Arkansas, Idaho, Mississippi, South Carolina, South Dakota, West Virginia, Wyoming) require failure of two alternative medications before covering lisdexamfetamine under Medicaid. Three states cap Medicaid coverage of Schedule II stimulants at patients under age 25 unless an exception is filed 4.

The 340B Drug Pricing Program, available at federally qualified health centers, reduces lisdexamfetamine costs to $15-$40/month for eligible patients. Modafinil through 340B pricing drops to $5-$15/month. Patients treated at community health centers, Ryan White clinics, or disproportionate-share hospitals should ask about 340B pricing before filling at retail pharmacies.

Telehealth Access in 2026

The post-pandemic telehealth regulatory environment favors modafinil access. With the expiration of COVID-era Schedule II telehealth waivers in late 2025, many states now require an initial in-person visit before prescribing lisdexamfetamine via telehealth. Subsequent refill visits can occur virtually, but that first appointment must be face-to-face.

Modafinil carries no such requirement anywhere in the United States. A patient can complete an initial evaluation, receive a prescription, and obtain medication entirely through virtual care platforms. For patients in rural areas, those with mobility limitations, or those who simply prefer the convenience of telehealth, this represents a meaningful access advantage.

The DEA proposed a permanent telehealth framework in early 2026 that would maintain the in-person requirement for Schedule II initial prescriptions while creating a narrow exception for board-certified sleep medicine and psychiatry specialists 3. That rule remains in public comment as of May 2026.

Patients starting lisdexamfetamine through HealthRX's telehealth platform should expect to complete one in-person visit at a partner clinic before transitioning to virtual follow-ups every 30 days for prescription renewal.